Novo Nordisk A/S (NYSE:NVO) Shares Sold by Transform Wealth LLC

Transform Wealth LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 96.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 3,685 shares of the company's stock after selling 91,632 shares during the quarter. Transform Wealth LLC's holdings in Novo Nordisk A/S were worth $259,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Victory Capital Management Inc. lifted its position in Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after buying an additional 23,223 shares during the last quarter. Bryn Mawr Capital Management LLC increased its stake in Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after purchasing an additional 30,420 shares during the period. DSM Capital Partners LLC increased its stake in shares of Novo Nordisk A/S by 16.7% during the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock valued at $172,678,000 after buying an additional 286,912 shares during the period. Channing Global Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $354,000. Finally, Compagnie Lombard Odier SCmA boosted its position in Novo Nordisk A/S by 5.0% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 67,745 shares of the company's stock valued at $5,827,000 after purchasing an additional 3,200 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 1.4%

NYSE NVO traded down $1.15 during trading on Friday, hitting $79.90. The company's stock had a trading volume of 7,465,072 shares, compared to its average volume of 7,042,462. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market cap of $358.57 billion, a PE ratio of 24.29, a P/E/G ratio of 0.90 and a beta of 0.66. The business's 50 day simple moving average is $67.30 and its 200-day simple moving average is $79.63. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.